MandalMed is is developing therapeutic products for fibrosis stemming from breakthroughs in innate immunity and glycobiology. MandalMed is seeking funding for completion of preclinical development and Phase 1 clinical trials of a human protein inhibitor of galectin-3, MM-003, which has blockbuster potential in treating cardiac fibrosis after myocardial infarction (MI) and in heart failure. Clinical trials can be biomarker directed because in HF patients an elevated serum level of galectin-3 is indicative of increased mortality, and at the time of MI an increased plasma level is an independent predictor of mortality and HF. Promising data with MM-003 treatment has been obtained in ischemia-reperfusion and permanent ligation models of MI. Current focus is on a large animal model of MI, IND-enabling toxicology, and animal models of liver fibrosis. No therapies are approved for cardiac or liver fibrosis. A small molecule program is aimed at a related target for liver fibrosis.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):